71 related articles for article (PubMed ID: 10209490)
1. Cycling activity of benign prostatic epithelial cells during long-term androgen blockade: evidence for self-renewal of luminal cells.
van der Kwast TH; Têtu B; Suburu ER; Gomez J; Lemay M; Labrie F
J Pathol; 1998 Dec; 186(4):406-9. PubMed ID: 10209490
[TBL] [Abstract][Full Text] [Related]
2. Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy.
Kruithof-Dekker IG; Têtu B; Janssen PJ; Van der Kwast TH
J Urol; 1996 Sep; 156(3):1194-7. PubMed ID: 8709345
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy.
Van der Kwast TH; Têtu B; Fradet Y; Dupont A; Gomez J; Cusan L; Diamond P; Labrie F
Prostate; 1996 Apr; 28(4):227-31. PubMed ID: 8602398
[TBL] [Abstract][Full Text] [Related]
5. Difficulties in interpreting specimens after neoadjuvant hormonal therapy and radiation with illustration of neuroendocrine differentiation.
Civantos F
Mol Urol; 2000; 4(3):117-21; discussion 123. PubMed ID: 11062365
[TBL] [Abstract][Full Text] [Related]
6. Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones.
Kirschenbaum A; Liu XH; Yao S; Narla G; Friedman SL; Martignetti JA; Levine AC
Carcinogenesis; 2006 Feb; 27(2):216-24. PubMed ID: 16123118
[TBL] [Abstract][Full Text] [Related]
7. [Histological investigation of prostate cancer treated with hormonal agents].
Azumi M; Saga Y; Hashimoto H; Kakizaki H
Hinyokika Kiyo; 2006 Oct; 52(10):781-4. PubMed ID: 17131867
[TBL] [Abstract][Full Text] [Related]
8. Prostatic basal cells in the peripheral and transitional zones: zonal variation in morphology and in immunophenotype.
Garcia FU; Haber MM; Chen X
Prostate; 2007 Nov; 67(15):1686-92. PubMed ID: 17879949
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
Penson DF; Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M
J Urol; 2005 Aug; 174(2):547-52; discussion 552. PubMed ID: 16006889
[TBL] [Abstract][Full Text] [Related]
10. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
11. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
[TBL] [Abstract][Full Text] [Related]
12. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
[TBL] [Abstract][Full Text] [Related]
13. [The effect of combined endocrine therapy on prostate and testis].
Kong X; Zeng L; Xia T; Wang J; Mi P; Na Y; Xue Z; Pan B; Hao J; Gu F; Guo Y
Zhonghua Wai Ke Za Zhi; 1999 Apr; 37(4):231-4. PubMed ID: 11829828
[TBL] [Abstract][Full Text] [Related]
14. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
15. Morphological changes induced by androgen blockade in normal prostate and prostatic carcinoma.
Têtu B
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):271-83. PubMed ID: 18471785
[TBL] [Abstract][Full Text] [Related]
16. The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume.
Stone NN; Stock RG
J Urol; 2007 Mar; 177(3):925-8. PubMed ID: 17296377
[TBL] [Abstract][Full Text] [Related]
17. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
18. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
[TBL] [Abstract][Full Text] [Related]
19. Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.
Bogdanos J; Karamanolakis D; Milathianakis C; Repousis P; Tsintavis A; Koutsilieris M
Anticancer Res; 2003; 23(2C):1757-62. PubMed ID: 12820454
[TBL] [Abstract][Full Text] [Related]
20. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M; Penson D
Urology; 2005 Oct; 66(4):835-9. PubMed ID: 16230148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
